Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene

Bromodomain and extraterminal domain inhibitors (BETi) represent promising therapeutic agents for metastatic melanoma, yet their mechanism of action remains unclear. Here we interrogated the transcriptional effects of BETi and identified AMIGO2, a transmembrane molecule, as a BET target gene essenti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cell 2017-11, Vol.68 (4), p.731-744.e9
Hauptverfasser:	Fontanals-Cirera, Barbara, Hasson, Dan, Vardabasso, Chiara, Di Micco, Raffaella, Agrawal, Praveen, Chowdhury, Asif, Gantz, Madeleine, de Pablos-Aragoneses, Ana, Morgenstern, Ari, Wu, Pamela, Filipescu, Dan, Valle-Garcia, David, Darvishian, Farbod, Roe, Jae-Seok, Davies, Michael A., Vakoc, Christopher R., Hernando, Eva, Bernstein, Emily
Format:	Artikel
Sprache:	eng
Schlagworte:	AMIGO2 Antineoplastic Agents - pharmacology apoptosis BET BET inhibition BRD2 BRD4 Cell Adhesion Molecules - metabolism Cell Cycle Proteins Cell Line, Tumor Cell Survival - drug effects cell viability Enhancer Elements, Genetic enhancers Female gene editing genes Humans Male mechanism of action melanocytes melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - metabolism Melanoma - pathology metastasis Neoplasm Metastasis Neoplasm Proteins - metabolism Nerve Tissue Proteins - genetics Nerve Tissue Proteins - metabolism Nuclear Proteins - genetics Nuclear Proteins - metabolism Protein Serine-Threonine Kinases - genetics Protein Serine-Threonine Kinases - metabolism proteolysis PTK7 Receptor Protein-Tyrosine Kinases - metabolism regulatory sequences therapeutics tissues transcription (genetics) Transcription Factors - genetics Transcription Factors - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!